ZLAB

SEC source: 0001567619-21-017211 · doc1.xml · nonDerivative · entry 2

Fu Tao · CIK 0001644888 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,522

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: Reflects a weighted average sale price of $124.98 per share, at prices ranging from $124.54 to $125.36 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-017211 · doc1.xml · nonDerivative · entry 1

Fu Tao · CIK 0001644888 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-017605 · doc1.xml · nonDerivative · entry 1

Fu Tao · CIK 0001644888 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,500

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-016964 · doc1.xml · derivative · entry 11

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,334

Underlying: Ordinary Shares · 10,000 shares

Expires 2027-05-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F11 · derivative.exercise_date: The options vest in equal annual installments over four years beginning on 5/12/2018, the first anniversary of the date of grant.

SEC source: 0001567619-21-016964 · doc1.xml · nonDerivative · entry 10

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F10 · price: Reflects a weighted average sale price of $146.61 per share, at prices ranging from $146.50 to $146.76 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016964 · doc1.xml · nonDerivative · entry 9

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F9 · price: Reflects a weighted average sale price of $146.07 per share, at prices ranging from $145.49 to $146.46 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016964 · doc1.xml · nonDerivative · entry 8

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,900

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F8 · price: Reflects a weighted average sale price of $144.35 per share, at prices ranging from $144.09 to $144.99 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016964 · doc1.xml · nonDerivative · entry 7

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,700

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F7 · price: Reflects a weighted average sale price of $143.34 per share, at prices ranging from $142.81 to $143.72 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016964 · doc1.xml · nonDerivative · entry 6

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,300

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F6 · price: Reflects a weighted average sale price of $141.92 per share, at prices ranging from $141.47 to $142.30 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016964 · doc1.xml · nonDerivative · entry 5

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F5 · price: Reflects a weighted average sale price of $140.87 per share, at prices ranging from $140.47 to $141.26 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016964 · doc1.xml · nonDerivative · entry 4

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,800

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F4 · price: Reflects a weighted average sale price of $139.27 per share, at prices ranging from $139.05 to $139.36 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016964 · doc1.xml · nonDerivative · entry 3

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,369

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: Reflects a weighted average sale price of $138.33 per share, at prices ranging from $137.89 to $138.67 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016964 · doc1.xml · nonDerivative · entry 2

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,269

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: Reflects a weighted average sale price of $137.39 per share, at prices ranging from $136.81 to $137.74 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016964 · doc1.xml · nonDerivative · entry 1

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-016869 · doc1.xml · nonDerivative · entry 8

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,008,653

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-016869 · doc1.xml · nonDerivative · entry 7

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,008,832

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F7 · price: Reflects a weighted average sale price of $151.83 per share, at prices ranging from $151.58 to $152.53 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016869 · doc1.xml · nonDerivative · entry 6

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,012,132

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F6 · price: Reflects a weighted average sale price of $151.10 per share, at prices ranging from $150.58 to $151.57 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016869 · doc1.xml · nonDerivative · entry 5

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,032,384

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F5 · price: Reflects a weighted average sale price of $150.05 per share, at prices ranging from $149.57 to $150.53 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016869 · doc1.xml · nonDerivative · entry 4

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,036,160

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F4 · price: Reflects a weighted average sale price of $148.97 per share, at prices ranging from $148.52 to $149.37 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016869 · doc1.xml · nonDerivative · entry 3

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,036,809

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: Reflects a weighted average sale price of $147.90 per share, at prices ranging from $147.50 to $148.04 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016869 · doc1.xml · nonDerivative · entry 2

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,036,895

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: Reflects a weighted average sale price of $146.73 per share, at prices ranging from $146.41 to $147.32 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016869 · doc1.xml · nonDerivative · entry 1

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,038,056

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-016870 · doc1.xml · derivative · entry 8

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,334

Underlying: Ordinary Shares · 10,000 shares

Expires 2027-05-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F7 · derivative.exercise_date: The options vest in equal annual installments over four years beginning on 5/12/2018, the first anniversary of the date of grant.

SEC source: 0001567619-21-016870 · doc1.xml · nonDerivative · entry 7

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F6 · price: Reflects a weighted average sale price of $152.11 per share, at prices ranging from $151.85 to $152.50 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016870 · doc1.xml · nonDerivative · entry 6

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 800

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F5 · price: Reflects a weighted average sale price of $151.28 per share, at prices ranging from $150.84 to $151.82 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016870 · doc1.xml · nonDerivative · entry 5

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,400

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F4 · price: Reflects a weighted average sale price of $150.41 per share, at prices ranging from $149.80 to $150.78 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016870 · doc1.xml · nonDerivative · entry 4

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,400

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: Reflects a weighted average sale price of $148.69 per share, at prices ranging from $148.23 to $148.92 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016870 · doc1.xml · nonDerivative · entry 3

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,700

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: Reflects a weighted average sale price of $146.98 per share, at prices ranging from $146.66 to $147.30 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016870 · doc1.xml · nonDerivative · entry 2

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,900

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-016870 · doc1.xml · nonDerivative · entry 1

Reinhart Harald · CIK 0001835824 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 16

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,038,438

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F16 · price: Reflects a weighted average sale price of $146.55 per share, at prices ranging from $146.39 to $146.79 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 15

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,039,686

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F15 · price: Reflects a weighted average sale price of $145.70 per share, at prices ranging from $145.38 to $146.36 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 14

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,049,127

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F14 · price: Reflects a weighted average sale price of $144.84 per share, at prices ranging from $144.37 to $145.37 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 13

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,056,500

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F13 · price: Reflects a weighted average sale price of $143.94 per share, at prices ranging from $143.32 to $144.31 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 12

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,062,583

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F12 · price: Reflects a weighted average sale price of $147.75 per share, at prices ranging from $147.27 to $148.27 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 11

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,063,640

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F11 · price: Reflects a weighted average sale price of $146.35 per share, at prices ranging from $146.18 to $147.11 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 10

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,072,211

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F10 · price: Reflects a weighted average sale price of $145.85 per share, at prices ranging from $145.17 to $146.17 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 9

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,084,070

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F9 · price: Reflects a weighted average sale price of $144.73 per share, at prices ranging from $144.15 to $145.15 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016760 · doc1.xml · derivative · entry 17

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 889,165

Underlying: Ordinary Shares · 111,111 shares

Expires 2025-10-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F17 · derivative.exercise_date: The Stock Options fully vested as of October 22, 2020.

SEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 8

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,091,321

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F8 · price: Reflects a weighted average sale price of $149.63 per share, at prices ranging from $149.58 to $149.63 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 7

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,091,497

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F7 · price: Reflects a weighted average sale price of $148.77 per share, at prices ranging from $148.35 to $149.22 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 6

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,095,266

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F6 · price: Reflects a weighted average sale price of $147.63 per share, at prices ranging from $147.28 to $148.15 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 5

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,102,199

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F5 · price: Reflects a weighted average sale price of $146.96 per share, at prices ranging from $146.27 to $147.27 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 4

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,109,025

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F4 · price: Reflects a weighted average sale price of $145.92 per share, at prices ranging from $145.24 to $146.24 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 3

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,110,907

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F3 · price: Reflects a weighted average sale price of $144.62 per share, at prices ranging from $144.09 to $145.01 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 2

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,115,598

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F2 · price: Reflects a weighted average sale price of $143.77 per share, at prices ranging from $143.07 to $144.07 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 1

Du Ying · CIK 0001731790 · Director · Chairwoman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,119,764

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

SEC source: 0001567619-21-016385 · doc1.xml · derivative · entry 7

Fu Tao · CIK 0001644888 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 430,000

Underlying: Ordinary Shares · 10,000 shares

Expires 2028-09-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F7 · derivative.exercise_date: The Stock Options vest in equal annual installments over five years beginning on 09/24/2019, the first anniversary of the date of grant.

SEC source: 0001567619-21-016385 · doc1.xml · nonDerivative · entry 5

Fu Tao · CIK 0001644888 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,000

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F5 · price: Reflects a weighted average sale price of $144.51 per share, at prices ranging from $144.45 to $144.56 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-21-016385 · doc1.xml · nonDerivative · entry 4

Fu Tao · CIK 0001644888 · Director · President & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,200

F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

F4 · price: Reflects a weighted average sale price of $143.76 per share, at prices ranging from $143.32 to $144.22 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.